Drug Profile
Research programme: pharmaceutical compounds - Xsira/SCYNEXIS
Alternative Names: Pharmaceutical compounds research programme - Xsira/SCYNEXISLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator SCYNEXIS
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Undefined in USA
- 07 Jan 2005 Norak Biosciences is now called Xsira Pharmaceuticals
- 13 Apr 2004 Preclinical trials in Undefined in USA (unspecified route)